Denali Therapeutics Inc.
DNLI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DNLI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DNLI
Denali Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases by leveraging its blood-brain barrier platform technology, with a pipeline in clinical trials and a history of operating losses.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.84B
Cash Runway
21.7 moLead Asset
avlayah (Approved)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 10 clinical trials · 3 catalysts · 1 FDA decision for Denali Therapeutics Inc..
Denali Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases by leveraging its blood-brain barrier platform technology, with a pipeline in clinical trials and a history of operating losses.
- Denali Therapeutics is developing product candidates for neurodegenerative diseases using its blood-brain barrier (BBB) platform technology [sec_mda · as of 2026-05-07].
- As of June 30, 2026, the company reported cash and equivalents of $204.6M, total revenue of $3.6M, and a net loss of -$127.6M [sec].
- The company has an accumulated deficit of $2.18 billion as of March 31, 2026 [sec_mda · as of 2026-05-07].
- Denali has collaborations with Takeda, Sanofi, Biogen, and Royalty Pharma, among others [sec_mda · as of 2026-05-07].
- The company faces risks typical of drug development, including uncertainty in clinical trial enrollment, regulatory approval, and commercialization [sec_mda · as of 2026-08-06].
What works
- Denali's blood-brain barrier platform technology is a proprietary approach that could enable drug delivery to the brain, addressing a key challenge in neurodegenerative disease treatment [sec_mda · as of 2026-05-07].
- The company has established multiple collaborations with major pharmaceutical partners (Takeda, Sanofi, Biogen, Royalty Pharma), providing non-dilutive funding and validation [sec_mda · as of 2026-05-07].
- Denali has a pipeline of clinical-stage candidates with upcoming catalysts, including Phase 2 and Phase 3 readouts, indicating active development progress [catalyst_timeline].
What to weigh
- Denali has a history of significant operating losses, with a net loss of $127.6M for the six months ended June 30, 2026, and an accumulated deficit of $2.18 billion as of March 31, 2026 [sec, sec_mda · as of 2026-05-07].
- The company is unable to predict when, if ever, material net cash inflows will commence from product sales or licensing, highlighting uncertainty in revenue generation [sec_mda · as of 2026-05-07].
- Drug development is subject to numerous risks, including the ability to enroll clinical trials, establish safety profiles, and obtain regulatory approval, which could delay or prevent commercialization [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Denali has incurred significant operating losses and expects to continue doing so.
“We have incurred significant operating losses to date and expect to continue to incur operating losses for the foreseeable future.”
SEC MD&A · May 7, 2026
Denali's platform technology focuses on the blood-brain barrier.
“the development of our blood-brain barrier ("BBB") platform technology, programs, and biomarkers”
SEC MD&A · May 7, 2026
The company has collaborations with Takeda, Sanofi, Biogen, and Royalty Pharma.
“payments received from our collaboration, synthetic royalty and other funding agreements with Takeda, Sanofi, Biogen, Royalty Pharma and other third parties.”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Phase 2 Readout: pipeline candidate — Top-line data from a Phase 2 trial of a pipeline candidate are expected, which could inform further development.
- 2027-06-01 · Phase3_Topline — Phase 3 Topline: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in — Top-line results from an open-label extension study of DNL310 are anticipated, assessing long-term safety and efficacy.
- 2027-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tiv — Top-line data from a Phase 2/3 study of tividenofusp alfa are expected, evaluating efficacy and safety.
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainty — Risks include enrollment challenges, safety profile establishment, and regulatory approval [sec_mda · as of 2026-08-06].
- Revenue generation delay — Material net cash inflows from product sales or licensing are unpredictable [sec_mda · as of 2026-05-07].
- Accumulated deficit — Accumulated deficit of $2.18 billion as of March 31, 2026, with ongoing losses [sec_mda · as of 2026-05-07].
- Geopolitical and pandemic risks — External events like geopolitical uncertainty and pandemics can impact operations [sec_mda · as of 2026-08-06].
What to watch
- Phase 2 top-line data readout expected by December 31, 2026 [catalyst_timeline].
- Phase 3 top-line data for DNL310 expected by June 1, 2027 [catalyst_timeline].
- Phase 3 top-line data for tiv (likely tividenofusp alfa) expected by December 1, 2027 [catalyst_timeline].
- Cash runway and ability to fund operations given $204.6M cash as of June 30, 2026 and ongoing losses [sec].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Denali Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Denali Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
21.7 months
D/E 0.39 · 0% dilution
Lead: Approved
3 candidates
3 upcoming, next in ~123d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
265
Total value held
$2.35B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,034,434 | $250.3M |
| vanguard capital management llc | 12,295,914 | $236.1M |
| state street corp | 6,272,001 | $120.4M |
| vanguard portfolio management llc | 6,120,160 | $117.5M |
| fmr llc | 4,575,374 | $87.8M |
| crestline management, l.p. | 4,421,464 | $84.9M |
| goldman sachs group inc | 4,407,255 | $84.6M |
| baker bros. advisors lp | 3,731,695 | $71.6M |
| geode capital management, llc | 3,727,114 | $71.6M |
| holocene advisors, lp | 3,195,429 | $61.4M |
Showing top 10 of 265 institutional holders of Denali Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 9.9%
- Days to cover
- 9.9
- Shares short
- 14,813,936
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DNLI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Denali Therapeutics Inc.?
Denali Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases by leveraging its blood-brain barrier platform technology, with a pipeline in clinical trials and a history of operating losses.
What is Denali Therapeutics Inc.'s lead drug candidate?
Denali Therapeutics Inc.'s most advanced tracked candidate is avlayah (Approved).
What is Denali Therapeutics Inc.'s next catalyst?
Denali Therapeutics Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pipeline candidate" — expected December 31, 2026.
Who is the CEO of Denali Therapeutics Inc.?
Dr. Ryan J. Watts Ph.D. is the chief executive officer of Denali Therapeutics Inc. (DNLI).
Where is Denali Therapeutics Inc. headquartered?
Denali Therapeutics Inc. (DNLI) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.